Beta Drugs Ltd

- Currently, Beta Drugs Limited has no explicit mention of new fundraising plans through debt or equity in the call. - The company has maintained some cash reserves mainly for new product development, inorganic growth opportunities, and potential biosimilar in-licensing. - Existing borrowings, including convertible debentures, are expected to be converted by June next year, which will reduce leverage. - No specific new issuance of debt or equity was discussed during the call. - The management emphasized using cash reserves for CAPEX, including the oncology intermediate plant and R&D facilities, but no fundraising linked to these was mentioned.

- Beta Drugs acquired an oncology intermediate plant with a CAPEX of around Rs.9.45 crores; additional Rs.15-20 crores planned for building and machinery to operationalize it within 6-8 months. - Purchased land for an intermediate plant and a corporate R&D center; final payments pending due to registry processes. - Fixed asset additions amounting to approximately Rs.25 crores in H1FY26, including expenditure on buildings. - Cash reserves are being held for new product development, potential inorganic growth opportunities, and in-licensing biosimilars. - The company is planning biosimilar development with ongoing discussions and NDAs, aiming for product launches in 3-4 years. - Investment in capacity expansion at Adley formulation plant to support domestic sales and CDMO growth.

- Beta Drugs plans to grow at a robust pace of 20-25% annually, as emphasized multiple times in the call. - Export sales are expected to see significant growth in the second half of FY26, potentially crossing Rs.100 crores, up from Rs.43 crores in the first half. - The CDMO business grew 8% YoY and is expected to maintain steady contributions by adding new products and partners. - In the domestic market, new molecule launches and own branded products are expected to drive growth, including two NDDS products planned for next year. - The dermatology/cosmetic division aims for Rs.30-50 crores in sales over the next 3-5 years, focusing on scaling current SKUs before launching new ones. - In-licensing and biosimilars are strategic growth areas, with potential product launches in 3-4 years. - Overall, the company targets sustained top-line growth backed by product pipeline expansions and entry into new regulated markets.

- Beta Drugs aims to grow at a consistent pace of 20-25% annually, backed by a robust pipeline and strong execution (Page 15, Rahul Batra closing comments). - EBITDA margins are expected to remain stable between 23% and 25% for FY26 (Page 8). - Exports, currently tender-driven with slower first-half performance, are expected to grow significantly in the second half, potentially crossing Rs.100 crores (Page 12). - Development of new products, including three drug filings and two new NDDS next year, will drive growth over the next 3-5 years (Page 5). - Growth will also be supported by expansion in derma/cosmetic business projected to reach Rs.30-50 crores per year in 3-5 years (Page 10). - Biosimilar entry planned within 3-4 years, potentially adding new revenue streams (Page 11). - Working capital and receivables expected to normalize with volume growth; no major impact anticipated on profitability (Pages 13-14).

- The company had an order book that could not be processed fully by September, resulting in Rs.10-12 crores of orders to be dispatched in October and November (Page 11). - Exports are tender-driven, with most tenders awarded between October and December, leading to expected higher sales from January onwards (Pages 7 and 12). - In October alone, three major tenders were filed, with two more planned in different geographies soon (Page 12). - The company expects export revenues to cross Rs.100 crores in the second half of FY26, nearly doubling from Rs.43 crores in the first half (Page 12). - The order backlog and tender pipeline indicate strong growth momentum to meet the annual target growth of 20-25% (Pages 11 and 12).